Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05199714
Other study ID # 2022-8225
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 21, 2022
Est. completion date March 25, 2023

Study information

Verified date October 2023
Source McGill University Health Centre/Research Institute of the McGill University Health Centre
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators aim to assess the glycemic outcomes of a fully automated insulin-and-pramlintide artificial pancreas and a comparator insulin-alone artificial pancreas with carbohydrate matched boluses.


Description:

The aim of this pilot study is to generate additional data of (i) a Fiasp-alone artificial pancreas with carbohydrate-matched boluses, compared to (ii) a Fiasp-plus-Pramlintide fully automated artificial pancreas with no meal announcement in an outpatient free-living setting. The study is not powered, nor aims to answer a scientific hypothesis related to the efficacy of the pramlintide and insulin closed-loop systems. Design The investigators will undertake a randomized crossover study to compare the following strategies: 1. Insulin-alone artificial pancreas with carbohydrate-matched boluses 2. Fiasp and pramlintide artificial pancreas with no meal announcement. Ratio of 1 unit of insulin for 8μg of pramlintide. 3. Fiasp and pramlintide artificial pancreas with no meal announcement. Ratio of 1 unit of insulin for 10μg of pramlintide. Each participant will be offered the opportunity to further participate in two optional additional arms: 4. Aspart and pramlintide artificial pancreas with no meal announcement. Ratio of 1 unit of insulin for 8μg of pramlintide. 5. Aspart and pramlintide artificial pancreas with no meal announcement. Ratio of 1 unit of insulin for 10μg of pramlintide. Aspart is used in this optional arm as it is the slower-acting version of Fiasp and can therefore be used to draw reasonable comparisons. Further, Aspart is an FDA approved insulin which is commonly sold and prescribed in North America. Several co-formulations are being developed with insulin, pramlintide, and glucagon. Given the widespread adoption and use of Aspart, it makes this insulin a good candidate for use in co-formulations and an excellent option for transition to market, where they will impact many individuals living with diabetes. Treatment period: Each intervention will last 14 hours. At-home run-ins, lasting two to four days, will occur prior to the pramlintide interventions. The interventions containing pramlintide with the same insulin will occur in sequence, one immediately after the other. The first pramlintide-and-Fiasp intervention will use a ratio of 8μg pramlintide/1unit of insulin and will be followed by the second pramlintide-and-Fiasp intervention the next day with a 10μg/1unit ratio. A similar schedule will be applied to the optional Aspart-and-pramlintide interventions. There will be a 2-29-day washout period between the Fiasp-and-pramlintide, Fiasp-alone, and Aspart-and-pramlintide interventions. Participants will be followed up remotely 1-2 days after the end of each intervention to ensure their washout period is going smoothly and will inquire about any adverse events. Remote contact can be performed via phone, email, text message or other reasonable communication channel. Participants will also be followed up remotely 1-2 days and 1-2 weeks after the end of their participation in the study.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date March 25, 2023
Est. primary completion date March 25, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Females and males = 18 years of age. - Clinical diagnosis of type 1 diabetes for at least 12 months. The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed. - Use of insulin pump therapy for at least 3 months. - Effective birth-control use in individuals of childbearing potential. Individuals of child-bearing potential must agree to use a highly effective method of birth control. Exclusion Criteria: - Current or = 1 month use of other antihyperglycemic agents (SGLT2I (sodium-glucose transporter), GLP-1(glucagon-like peptide), Metformin, etc.). - Current use of glucocorticoid medication (except low, stable does and inhaled steroids). - Individuals with confirmed gastroparesis. - Use of medication that alters gastrointestinal motility. - Planned or ongoing pregnancy. - Breastfeeding individuals. - Severe hypoglycemia requiring hospitalization in the past three months. - Severe diabetic ketoacidosis episode in the past three months. - Clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator. - Recent (< 6 months) acute macrovascular event e.g., acute coronary syndrome or cardiac surgery. - Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.

Study Design


Intervention

Drug:
Fiasp
Fiasp Insulin delivered in a basal-bolus manner.
Device:
Artificial Pancreas
Medtronic insulin pump, Dexcom G6 continuous glucose sensor, tablet running the Artificial Pancreas Algorithm.
Drug:
Pramlintide
Pramlintide delivered in a basal-bolus manner.
Aspart
Aspart insulin delivered in a basal-bolus manner.

Locations

Country Name City State
Canada Research Institute of the McGill University Health Center Montreal Quebec

Sponsors (2)

Lead Sponsor Collaborator
McGill University Health Centre/Research Institute of the McGill University Health Centre Juvenile Diabetes Research Foundation

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Safety Endpoints Adverse events including gastrointestinal symptoms (nausea, vomiting, diarrhea, bloating) 42 +/- 28 hours
Primary Each participant's percentage of time glucose levels spent in the target range Time in target range (3.9-10.0 mmol/L). 42 +/- 28 hours
Secondary Each participant's percentage of time of glucose levels spent between 3.9 and 7.8 mmol/L Glucose data will be collected from a glucose sensor and numerical glucose data will be analyzed as a function of time 42 +/- 28 hours
Secondary Each participant's percentage of time of glucose levels spent below 3.9 mmol/L Glucose data will be collected from a glucose sensor and numerical glucose data will be analyzed as a function of time 42 +/- 28 hours
Secondary Each participant's percentage of time of glucose levels spent below 3.0 mmol/L Glucose data will be collected from a glucose sensor and numerical glucose data will be analyzed as a function of time 42 +/- 28 hours
Secondary Each participant's percentage of time of glucose levels spent above 10.0 mmol/L Glucose data will be collected from a glucose sensor and numerical glucose data will be analyzed as a function of time 42 +/- 28 hours
Secondary Each participant's percentage of time of glucose levels spent above 13.9 mmol/L Glucose data will be collected from a glucose sensor and numerical glucose data will be analyzed as a function of time 42 +/- 28 hours
Secondary Each participant's percentage of time of glucose levels spent above 16.7 mmol/L Glucose data will be collected from a glucose sensor and numerical glucose data will be analyzed as a function of time 42 +/- 28 hours
Secondary Each participant's mean glucose levels 42 +/- 28 hours
Secondary Each participant's standard deviation of glucose levels 42 +/- 28 hours
Secondary Each participant's coefficient of variance of glucose levels 42 +/- 28 hours
Secondary Total pramlintide delivery for each participant 28 +/- 28 hours
Secondary Total insulin delivery for each participant 42 +/- 28 hours
Secondary Total basal insulin delivery for each participant 42 +/- 28 hours
Secondary Total bolus insulin delivery for each participant 42 +/- 28 hours
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Active, not recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Recruiting NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4
Completed NCT02855307 - Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes Phase 2